Download
g zero therapeutics n.
Skip this Video
Loading SlideShow in 5 Seconds..
G-Zero Therapeutics PowerPoint Presentation
Download Presentation
G-Zero Therapeutics

G-Zero Therapeutics

177 Views Download Presentation
Download Presentation

G-Zero Therapeutics

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. G-Zero Therapeutics Contact: John Chant, 650-307-7770; chant_john@hotmail.com

  2. 100 Minus 4 hrs (N=22) Percent Survival 50 Untreated (N=28) 0 0 10 20 30 40 Days after 7.5 Gy TBI Protection BEFORE Treatment Models Radioprotection and Chemoprotection Clinical Oncology Supportive Care

  3. Treating Bone Marrow Suppression Stem Cell G-Zero: PharmacoQuiescence™ (PQ™) Multi-potent Progenitors Common Lymphoid Progenitor Common Myeloid Progenitor Megakaryocyte-Erythroid Prog. Granulocyte-Monocyte Prog. Erythrocytes Platelets Granulocytes Macrophages T-cells B-cells EPO® Neupogen® Unmet* Unmet 4.3B 4.6B *Neumega ® (Wyeth)—very minor product

  4. All Lineages Protected Nadir blood counts 21 days after 7.5 Gy of TBI 60 600 4.0 2.0 0.8 45 450 3.0 1.5 0.5 Percent 103 / uL 103 / uL 103 / uL 103 / uL 30 300 2.0 1.0 0.3 15 150 1.0 0.5 # # Total White Blood Count Hematocrit Platelets Lymphocytes Myeloid Cells Untreated (n=4) Treated (n=5) 9

  5. Proprietary small molecule therapeutics that prevent bone marrow suppression Novel method: no other small molecule does this Intellectual property from Sharpless Lab Technology

  6. Applications • Protect bone marrow during chemotherapy for cancer • $5B+ market per year • Government sponsored market: radiation mitigation • $200-250M contracts available so stockpile • Generous non-dilutive financing: SBIR, etc. G-Zero Technology is Demonstrably Superior to Existing Treatments

  7. Research operations housed in Lineberger Comprehensive Cancer Center Subcontractors/Consultants in place Non-dilutive financing in place Current Status

  8. Founders Norman “Ned” Sharpless , MD Clinical Oncologist UNC Medical School, Lineberger Comprehensive Cancer Center Kwok-kin Wong, MD Ph D Clinical Oncologist Dana Farber Cancer Institute, Harvard Medical School John Chant Ph D President, G-Zero Therapeutics Former: Harvard University, CuraGen/454, Genentech Oncology

  9. Needs • To achieve proof of concept trial in humans for chemoprotection and approval for radioprotection $5M/2-3 years ** • To achieve NDA for chemoprotection $10M additional/additional 1-2 years ** **budget numbers do not account for government funding

  10. G-Zero Therapeutics Contact: John Chant, 650-307-7770; chant_john@hotmail.com